Table 4.
Results of the univariate analysis for relapse-free survival.
| Relapse-free survival | |||
|---|---|---|---|
| HR | p-value | 95% CI | |
| Age (Years) | |||
| <59.2 | 1 | ||
| ≥59.2 | 1.270 | 0.253 | 0.843 - 1.914 |
| Tumor size | |||
| T1 | 1 | ||
| T2 | 2.492 | <0.001 | 1.558 - 3.984 |
| T3/T4 | 6.316 | <0.001 | 3.218 - 12.396 |
| Node status | |||
| N- | 1 | ||
| N+ | 3.619 | <0.001 | 2.39 - 5.479 |
| Pathological stage | |||
| I | 1 | ||
| II | 2.334 | 0.005 | 1.298 – 4.195 |
| III | 9.522 | <0.001 | 5.213 – 17.393 |
| Histological grade | |||
| I / II | 1 | ||
| III | 0.898 | 0.665 | 0.553 - 1.459 |
| HER2 | |||
| Null | 1 | ||
| Low | 1.113 | 0.662 | 0.689 - 1.796 |
| Histology | |||
| NST | 1 | ||
| Lobular | 1.338 | 0.500 | 0.573 - 3.123 |
| Other | 0.659 | 0.279 | 0.310 - 1.401 |
| Adjuvant chemotherapy | |||
| No | 1 | ||
| Yes | 0.369 | <0.001 | 0.244 - 0.558 |
| Basal-like phenotype | |||
| Non-basal-like | 1 | ||
| Basal-like | 0.752 | 0.179 | 0.495 - 1.14 |
| Molecular apocrine phenotype | |||
| Non-molecular apocrine | 1 | ||
| Molecular apocrine | 1.352 | 0.157 | 0.89 - 2.055 |
| TILs | |||
| <30% | 1 | ||
| ≥30% | 0.474 | 0.004 | 0.286 - 0.786 |
| Inflammatory pattern | |||
| Cold | 1 | ||
| Excluded | 0.595 | 0.129 | 0.305 - 1.162 |
| Hot | 0.574 | 0.036 | 0.342 - 0.965 |
| Peritumoral TLS | |||
| None | 1 | ||
| Little | 0.584 | 0.068 | 0.328 - 1.041 |
| Moderate | 0.444 | 0.002 | 0.263 - 0.751 |
| Abundant | 0.177 | <0.001 | 0.076 - 0.416 |
| m-TLS (with CGC) | |||
| Absence | 1 | ||
| Presence | 0.650 | 0.133 | 0.371 - 1.14 |
| Intratumoral TLS | |||
| Absence | 1 | ||
| Presence | 1.051 | 0.837 | 0.653 - 1.693 |
| CD3+ cells* | |||
| Low | 1 | ||
| High | 0.555 | 0.018 | 0.341 - 0.903 |
| CD8+ cells* | |||
| Low | 1 | ||
| High | 0.904 | 0.63 | 0.598 - 1.365 |
| CD20+ cells* | |||
| Low | 1 | ||
| High | 0.482 | 0.002 | 0.303 - 0.769 |
| CD68+ cells* | |||
| Low | 1 | ||
| High | 0.717 | 0.23 | 0.417 - 1.233 |
| CD163+ cells* | |||
| Low | 1 | ||
| High | 0.514 | 0.039 | 0.273 - 0.967 |
| CD11b+ cells* | |||
| Low | 1 | ||
| High | 0.611 | 0.056 | 0.369 - 1.012 |
| CD66b+ cells* | |||
| Low | 1 | ||
| High | 1.082 | 0.75 | 0.667 - 1.755 |
| PD1+ cells | |||
| 0 | 1 | ||
| ]0-10[ | 0.884 | 0.676 | 0.496 - 1.574 |
| ≥10% | 0.845 | 0.544 | 0.490 - 1.457 |
| PD-L1+ tumor cells | |||
| <1% | 1 | ||
| ≥1% | 0.626 | 0.034 | 0.406 - 0.965 |
| PD-L1+ stromal cells | |||
| 0 | 1 | ||
| ]0-10[ | 1.395 | 0.302 | 0.742 - 2.623 |
| ≥10% | 0.682 | 0.241 | 0.360 - 1.292 |
| TIGIT+ cells* | |||
| Low | 1 | ||
| High | 0.627 | 0.067 | 0.381 - 1.033 |
| PVR+ cells§ | |||
| Low | 1 | ||
| High | 0.538 | 0.034 | 0.304 - 0.955 |
HR: hazard ratio; Basal-like phenotype was defined by the expression of cytokeratin 5/6 and/or EGFR in >10% of tumor cells; molecular apocrine phenotype was considered in the case of positive staining for both androgen receptor and Forkhead box protein A1 (FoxA1) biomarkers in ≥1% of tumor cells. TILs, tumor-inflitrating lymphocytes; TLS, tertiary lymphoid structures; m-TLS, mature-TLS; CGC, clear germinal center. Low and high density categories were defined according to the median* and for PVR, by grouping the two first terciles versus the third§ (see Materials and Methods).